lystn

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
A Guideline Approach to Managing Diabetes: Improving Outcomes with GLP-1 RA Therapy Podcast

Featuring James R. Gavin III, MD, PhD as faculty, moderated by Gregg Sherman, MD.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a relatively newer drug group for type 2 diabetes (T2DM) management, which demonstrate excellent efficacy for glycemic control. They reduce HbA1c and have low glycemic variability and a low risk of hypoglycemia. GLP-1 RAs also delay gastric emptying, reduce appetite, and promote weight loss. Subsequently, GLP-1 RAs are the preferred agents to treat T2DM patients in whom there is a compelling need to minimize hypoglycemia or to minimize weight gain/promote weight loss. Initiating therapy with a GLP-1 RA ahead of insulin may be preferred for patients who need an injectable’s greater glucose-lowering effect. Recent cardiovascular outcome trials (CVOTs) have also demonstrated the cardiorenal benefits of some GLP-1 RAs, and these agents are indicated for T2DM patients who have atherosclerotic cardiovascular disease (ASCVD) or indicators of high risk, established kidney disease or heart failure. This course will address diagnosis, treatment, and clinician-patient communication strategies to optimize patient care.

This podcast was recorded and is being used with the permission of the presenters.

Learning Objectives

Upon completion of this activity, learners should be able to:

• Describe the glycemic and non-glycemic benefits of various GLP-1 receptor agonists that are currently available as well as the patient profile for which GLP-1 receptor agonists produced the best outcomes
• Optimize treatment selection of GLP-1 receptor agonist therapy for patients with type 2 diabetes (T2D) based on current guidelines, patient characteristics, and evolving outcome data
• Utilize effective communication to optimize shared decision-making and involve patients in discussions concerning GLP-1 receptor agonist therapy in order to decrease barriers to care, improving adherence, decrease cardiovascular risk, and optimize patient outcomes

This activity is accredited for CME/CE credit.
 
 For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
A Guideline Approach to Managing Diabetes: Improving Outcomes with GLP-1 RA Therapy Podcast

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).

This educational activity is supported by an educational grant from Novo Nordisk, Inc.